Collegium Pharmaceutical Inc.

18.30+1.04+6.03%Vol 766.15K1Y Perf -28.53%
Jun 24th, 2022 16:00 DELAYED
BID7.18 ASK21.39
Open17.30 Previous Close17.26
Pre-Market- After-Market18.30
 - -  - -%
Target Price
27.71 
Analyst Rating
Moderate Buy 1.63
Potential %
51.42 
Finscreener Ranking
★+     42.77
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★+     44.12
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★+     54.23
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
36.66 
Earnings Rating
Strong Sell
Market Cap621.71M 
Earnings Date
4th Aug 2022
Alpha0.02 Standard Deviation0.19
Beta1.06 

Today's Price Range

17.1918.31

52W Range

14.0425.66

5 Year PE Ratio Range

-19.4035.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
15.60%
1 Month
14.73%
3 Months
-5.33%
6 Months
-5.96%
1 Year
-28.53%
3 Years
45.01%
5 Years
42.52%
10 Years
-

TickerPriceChg.Chg.%
COLL18.301.04006.03
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.00
0.78
3.97
-0.60
Leverage Ratio 3.80
ProfitabilityValueIndustryS&P 500US Markets
52.60
-5.00
21.20
-83.50
14.92
RevenueValueIndustryS&P 500US Markets
272.90M
8.03
-1.69
100.09
Earnings HistoryEstimateReportedSurprise %
Q01 20220.820.42-48.78
Q04 20210.86-0.73-184.88
Q03 20210.750.22-70.67
Q02 20210.340.27-20.59
Q01 20210.300.4136.67
Q04 20200.290.20-31.03
Q03 20200.230.3239.13
Q02 20200.240.23-4.17
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.26-3.82Negative
9/2022 QR1.29-12.84Negative
12/2022 FY4.89-5.23Negative
12/2023 FY6.20-15.76Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report1.26
Estimates Count5
EPS Growth Next 5 Years %20.00
Volume Overview
Volume766.15K
Shares Outstanding33.97K
Shares Float24.34M
Trades Count8.01K
Dollar Volume13.79M
Avg. Volume345.68K
Avg. Weekly Volume399.81K
Avg. Monthly Volume306.25K
Avg. Quarterly Volume330.96K

Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 18.3 per share at the end of the most recent trading day (a 6.03% change compared to the prior day closing price) with a volume of 766.15K shares and market capitalization of 621.71M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.

The one-year performance of Collegium Pharmaceutical Inc. stock is -28.53%, while year-to-date (YTD) performance is -2.03%. COLL stock has a five-year performance of 42.52%. Its 52-week range is between 14.04 and 25.66, which gives COLL stock a 52-week price range ratio of 36.66%

Collegium Pharmaceutical Inc. currently has a PE ratio of 14.90, a price-to-book (PB) ratio of 2.74, a price-to-sale (PS) ratio of 1.97, a price to cashflow ratio of 10.80, a PEG ratio of 2.32, a ROA of 4.61%, a ROC of 7.71% and a ROE of 23.99%. The company’s profit margin is 14.92%, its EBITDA margin is 21.20%, and its revenue ttm is $272.90 Million , which makes it $8.03 revenue per share.

Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $1.26 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Moderate Buy (1.63), with a target price of $27.71, which is +51.42% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Collegium Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.07, ATR14 : 0.75, CCI20 : 284.08, Chaikin Money Flow : 0.21, MACD : 0.26, Money Flow Index : 82.30, ROC : 14.66, RSI : 68.94, STOCH (14,3) : 99.69, STOCH RSI : 1.00, UO : 63.13, Williams %R : -0.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Joseph Ciaffoni (Sold 76 094 shares of value $1 405 223 ), Scott Dreyer (Sold 10 559 shares of value $228 180 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
6 (75.00 %)
5 (71.43 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (12.50 %)
1 (12.50 %)
1 (14.29 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.63
Moderate Buy
1.71

Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. Its product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.

CEO: Joseph J. Ciaffoni

Telephone: +1 781 713-3699

Address: 100 Technology Center Drive, Stoughton 02072, MA, US

Number of employees: 234

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

TipRanks News for COLL

Thu, 14 Apr 2022 09:45 GMT Collegium Pharmaceutical (COLL) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Wed, 06 Apr 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL) and Atreca (BCEL)

- TipRanks. All rights reserved.

Tue, 05 Apr 2022 18:10 GMT Collegium Pharmaceutical (COLL) Receives a Buy from Needham

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 11:15 GMT Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), ImmunoGen (IMGN)

- TipRanks. All rights reserved.

News

Stocktwits